Column

Today, we’d like to make suggestions on how to maximize the value of your preclinical data you have obtained with us.

2 strategic approaches to expand the potential of drug development
We propose the following approaches for further expansion of your current drug development.

Proposal 1: Indication expansion strategy: Expanding disease area
In recent years, there has been growing attention to expanding the same test substance across multiple disease areas. A notable example is a research published in Nature Biotechnology by our customer Insilico Medicine (Ren et al., Nat Biotechnol., 2024), which demonstrated the efficacy of a TNIK inhibitor across multiple fibrosis models in lung, skin, and kidney, and has progressed to clinical trials.

We can design tests utilizing different organ fibrosis models to meet the following needs:
– Uncertain about which organ to target
– Compound effective for liver diseases, so curious about its potential in other organs
– Aiming to expand the pipeline’s indications

We have established evaluation systems for lung, liver, kidney, colon, and skin, and can propose test designs tailored to the characteristics of your compound.

Proposal 2: Building robust evidence with multiple disease models
For instance, in MASH diseases, we can evaluate by combining multiple MASH models with different characteristics and pathological mechanisms, such as the STAM model (lean type MASH) and DIAMOND model (obese type MASH) (Cheung-Flynn et al., Nutrients, 2025). This approach enables the construction of reproducible and compelling data regarding drug efficacy and mechanism of action.

Such an approach aligns with the FDA’s Animal Rule Guidance and serves as an effective differentiation resource for eliminating model dependency and developing strategic partnerships.

If this catches your eye, we would be grateful to discuss the details with you online.
We remain committed to contribute to your company’s research and development activities.